Interferon lambdas: The next cytokine storm

Gut

Volumn 60, Issue 9, 2011, Pages 1284-1293

  Kelly, Christabel ^a   Klenerman, Paul ^a   Barnes, Eleanor ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BIOLOGICAL MARKER; INTERLEUKIN 28B; INTERLEUKIN 29; PEGINTERFERON ALPHA; RIBAVIRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANXIETY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; DEPRESSION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INHIBITION KINETICS; INSOMNIA; LIVER DISEASE; MEDICAL RESEARCH; MYALGIA; NAUSEA; NEUTROPENIA; PATHOGENESIS; PATIENT CARE; PHARMACOGENOMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SLEEP DISORDER; THROMBOCYTOPENIA; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VIRAL CLEARANCE; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GENOME-WIDE ASSOCIATION STUDY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 80051550050     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.222976     Document Type: Review

References (53)

1. Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191:1499-512. (Pubitemid 30257347)
2. Thimme R, Oldach D, Chang KM, et al. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001;194:1395-406. (Pubitemid 33081515)
3. Neumann-Haefelin C, Timm J, Schmidt J, et al. The protective effect of HLA-B27 in hepatitis C virus infection requires presence of a genotype-specific immunodominant CD8+ T cell epitope. Hepatology 2010;51:54-62.
4. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-33. (Pubitemid 29181642)
5. McHutchison JG, Lawitz EJ, Shiffman ML, et al. PEGinterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93.
6. Muir AJ, Bornstein JD, Killenberg PG. PEGinterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004;350:2265-71. (Pubitemid 38669209)
7. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Hepatology 1999;30:787-93. (Pubitemid 29409425)
8. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
9. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45.
10. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009;41:1100-4.
11. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
12. Labie D, Gilgenkrantz H. IL28 (interferon lambda3) gene polymorphisms and response to IFN-alpha treatment in patients infected with hepatitis virus C. Med Sci 2010;26:225-6.
13. Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821-7.
14. Montes-Cano MA, Garcia-Lozano JR, Abad-Molina C, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010;52:33-7.
15. McCarthy JJ, Li JH, Thompson A, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology 2010;138:2307-14.
16. Mosbruger TL, Duggal P, Goedert JJ, et al. Large-scale candidate gene analysis of spontaneous clearance of hepatitis C virus. J Infect Dis 2010;201:1371-80.
17. Rallón NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-9.
18. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
19. Cirulli ET, Goldstein DB. Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet 2010;11:415-25.
20. Dickson SP, Wang K, Krantz I, et al. Rare variants create synthetic genome-wide associations. PLoS Biol 2010;8:e1000294.
21. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4:63-8. (Pubitemid 36104710)
22. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003;4:69-77. (Pubitemid 36109115)
23. Pagliaccetti NE, Robek MD. Interferon-λ in the immune response to hepatitis B virus and hepatitis C virus. J Interferon Cytokine Res 2010;30:585-90.
24. Coccia EM, Severa M, Giacomini E, et al. Viral infection and Tolllike receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004;34:796-805. (Pubitemid 39255927)
25. Megjugorac NJ, Gallagher GE, Gallagher G. IL-4 enhances IFN-λ1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra. Blood 2010;115:4185-90.
26. Siren J, Pirhonen J, Julkunen I, et al. IFN-λ regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29. J Immunol 2005;174:1932-7. (Pubitemid 40223933)
27. Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80:4501-9.
28. Wolk K, Witte K, Sabat R. Interleukin-28 and interleukin-29: novel regulators of skin biology. J Interferon Cytokine Res 2010;30:617-28.
29. Mihm S, Frese M, Meier V, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest 2004;84:1148-59. (Pubitemid 39128260)
30. Witte K, Gruetz G, Volk HD, et al. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009;10:702-14.
31. Doyle SE, Schreckhise H, Khuu-Duong K, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906. (Pubitemid 46489554)
32. Mennechet FJD. Interferon- -treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006;107:4417-23. (Pubitemid 43801368)
33. Dumoutier L, Tounsi A, Michiels T, et al. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem 2004;279:32269-74. (Pubitemid 39014676)
34. Renauld JC. Class II cytokine receptors and their ligands: key antiviral and inflammatory modulators. Nat Rev Immunol 2003;3:667-76.
35. Der SD, Zhou A, Williams BR, et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 1998;95:15623-8. (Pubitemid 29018750)
36. Rani MR, Foster GR, Leung S, et al. Characterization of beta-R1, a gene that is selectively induced by interferon beta (IFN-beta) compared with IFN-alpha. J Biol Chem 1996;271:22878-84. (Pubitemid 26304738)
37. Gad HH, Dellgren C, Hamming OJ, et al. Interferon-l is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009;284:20869-75.
38. Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131:1887-98. (Pubitemid 44958521)
39. Dai J, Megjugorac NJ, Gallagher GE, et al. IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 2009;113:5829-38.
40. Jordan WJ, Eskdale J, Srinivas S, et al. Human interferon lambda-1 (IFN-λ1//IL-29) modulates the Th1//Th2 response. Genes Immun 2007;8:254-61. (Pubitemid 46679436)
41. Srinivas S, Dai J, Eskdale J, et al. Interferon-λ1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008;125:492-502.
42. Morrow MP, Yan J, Pankhong P, et al. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol Ther 2010;18:1714-23.
43. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. J Leukoc Biol 2008;83:1181-93. (Pubitemid 351960350)
44. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005;79:3851-4. (Pubitemid 40327973)
45. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52:822-32.
46. Pagliaccetti NE, Eduardo R, Kleinstein SH, et al. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 2008;283:30079-89.
47. Fried MW, Shiffman ML, Reddy KR, et al. PEGinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
48. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. PEGinterferonalpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
49. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139:499-509.
50. Sarasin-Filipowicz M, Oakeley EJ, Duong FHT, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008;105:7034.
51. Chen L, Borozan I, Sun J, et al. Cell-type specific gene expression signature in liver underlies response to interferon therapy in chronic hepatitis C infection. Gastroenterology 2010;138:1123-33.
52. Muir AJ, Lawitz E, Ghalib RH, et al. Pegylated interferon lambda (pegIFNλ) phase 2 dose-ranging, active-controlled study in combination with ribavirin (RBV) for treatment-naïve HCV patients (genotypes 1, 2, 3 or 4): safety, viral response, and impact of IL28B host genotype through week 12. Hepatology 2010;52:715A-16A.
53. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-λ production in asthma exacerbations. Nat Med 2006;12:1023-6. (Pubitemid 44353382)